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ABSTRACT
Objectives: To evaluate the association between
restless legs syndrome (RLS) and all-cause mortality.
Design: Four prospective cohort studies.
Setting: The Dortmund Health Study (DHS) and the
Study of Health in Pomerania (SHIP) from Germany.
The Women’s Health Study (WHS) and the Physicians’
Health Study (PHS) from the USA.
Participants: In DHS: a random sample (n=1 299)
from the population of Dortmund; in SHIP: a sample
(n=4 291) from residents living in West Pomerania
were drawn by multistage random sampling design; in
WHS: female healthcare professionals (n=31 370); in
PHS: male physicians (n=22 926)
Main outcome measures: All-cause mortality.
Results: The prevalence of RLS ranged between 7.4%
and 11.9% at baseline. During follow-up (ranging
between 6 and 11 years) RLS was not associated with
increased risk of all-cause mortality in any of the four
cohorts. The multivariable-adjusted HRs (95% CI) for
all-cause mortality ranged from 0.21 (0.03 to 1.53) to
1.07 (0.93 to 1.23) across the four studies. The HRs
for all-cause mortality did not differ according to
gender.
Conclusions: In these four independently conducted
large prospective cohort studies from Germany and the
USA, RLS did not increase the risk of all-cause
mortality. These findings do not support the
hypothesis that RLS is a risk factor for mortality of any
cause.
INTRODUCTION
Restless legs syndrome (RLS) is a common
sleep-related movement disorder affecting
about 7–10% of the general population in
western countries.
1 RLS is characterised by
an urge to move the legs, typically accom-
panied by uncomfortable leg sensations and
both feelings are relieved by leg movement.
Symptoms emerge during inactivity and they
are worst in evening or night hours. The
prevalence and incidence of RLS increase
with age, and women are more commonly
affected.
12The exact pathophysiological
pathways of RLS remain unknown; the
impairment of the central dopaminergic
system and iron deﬁciency in the brain have
a key importance, but genetic risk variants
have also been identiﬁed.
3 RLS is frequently
associated with insomnia, impaired quality of
life and depression.
4–6
In recent years, results from several cross-
sectional studies suggested an association
between RLS and chronic diseases, especially
cardiovascular disorders, such as hyperten-
sion, stroke and myocardial infarction.
7–11
These are frequent disorders in the elderly
and associated with a clearly increased risk of
mortality. However, the relation between RLS
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the minimal criteria for RLS are lacking so far. The few
existing studies either examined clinic-based populations
or did not apply the four minimal diagnostic criteria for
RLS, which were ﬁrst introduced in 1995.
12 RLS was
reported to be a marker of higher mortality among
patients with chronic renal disease,
13–15 a condition
known to predispose to RLS. Among elderly community
dwelling female residents RLS was found to be related
to mortality.
16 Similarly, in a middle-aged sample from
the general population RLS was a risk factor for mortal-
ity only in women according to a 20-year follow-up
study.
17 Since case classiﬁcation relies entirely on self-
reported symptoms and disease characteristics, applica-
tion of the minimal criteria for RLS, deﬁned by the
International RLS Study Group, is important to allow
standardised RLS assessment across populations.
Despite the high prevalence and subjective burden of
RLS, it often remains unrecognised in primary care.
Given the high frequency of RLS in the general popula-
tion, an association between RLS and all-cause mortality
would have a substantial impact on the population level.
Once diagnosed, RLS can be successfully treated in
many cases. Thus, the evaluation of RLS as a novel modi-
ﬁable mortality risk factor has considerable public
health implications, and may result in more routine
screening and monitoring of RLS.
Therefore, the aim of this study was to investigate
whether RLS, assessed by the minimal criteria, is asso-
ciated with an increased risk of all-cause mortality in
four large, independent cohort studies, two from
Germany and two from the USA.
METHODS
The following four prospective cohort studies were
included in the analyses. All four studies applied the
minimal diagnostic criteria for RLS by using the same
short set of standardised questions,
12 either in German
or in English.
DORTMUND HEALTH STUDY
Primary aim of the Dortmund Health Study (DHS) was
to determine the frequency of headache disorders, car-
diovascular and other chronic diseases, and behaviour-
dependent risk factors in the population of the city of
Dortmund in the western part of Germany.
18 From a
total population of 591 000 a random sample of 3820
persons aged 25–75 years was drawn from the municipal
registry. Of those sampled, 395 persons were excluded
because they had moved out of the study area, died or
did not have sufﬁcient knowledge of the German lan-
guage leaving 3425 persons, who were eligible and
invited to participate in a personal interview at the DHS
study centre. If personal participation at the centre was
impossible, a questionnaire with a subset of the other-
wise identical questions was mailed to the participants.
The overall response at baseline was 66.9%, yielding
2291 participants (1312 with interview and 979 with
questionnaire). RLS assessment at baseline was restricted
to interviewed participants only, because the respective
questions were not included in the questionnaire due to
the reduced space available. Vital status of 13 subjects
could not be identiﬁed during the follow-up. Eight had
moved outside Germany and were not traceable, three
of the remaining ﬁve had foreign nationalities and were
likely to have moved abroad, and two were untraceable.
Therefore, the analyses included the data of 1299 parti-
cipants from DHS.
STUDY OF HEALTH IN POMERANIA
The Study of Health in Pomerania (SHIP) is an ongoing
population-based study comprising 3 cities and 29 com-
munities in the rural area close to the Baltic Sea (West
Pomerania). It was designed to assess a broad range of
health and quality-of-life indicators in the north-east
region of Germany after the German reuniﬁcation.
19
From the total population of 212 157 residents living in
the study area in 1995, a sample of 7008 men and
women aged 20–79 stratiﬁed by 5-year age groups was
drawn using a multistage random sampling design. The
ﬁnal number of subjects participating in the study was
4308 (response 68.8%). The baseline examination was
conducted from 1997 to 2001, combining an interview,
medical and dental examinations performed in one
single visit in the study centre. RLS data at baseline were
available from 4291 participants.
WOMEN’S HEALTH STUDY
The Women’s Health Study (WHS) was a randomised,
placebo-controlled trial designed to test the risks and
beneﬁts of low-dose aspirin (100 mg every other day)
and vitamin E (600 IU every other day) in the primary
prevention of cardiovascular diseases (CVD) and cancer
among apparently healthy women. The design and
methods of the WHS have been described in detail pre-
viously.
20 21 Brieﬂy, a total of 39 876 US female health-
care professionals aged 45 years or older at study entry
(1992–1995) without a history of CVD, cancer or other
major illnesses were randomly assigned to receive active
aspirin, active vitamin E, both active agents, or both pla-
cebos. Baseline information was self-reported and col-
lected by a mailed questionnaire that asked about many
cardiovascular risk factors and lifestyle variables. Twice
in the ﬁrst year and yearly thereafter, participants were
sent follow-up questionnaires asking about study out-
comes and other information during the study period.
After the trial’s termination in March 2004, the women
who were still alive and willing to participate entered an
observational follow-up. The return date of the
108-month questionnaire containing questions on RLS
was deﬁned as new baseline for this analysis. Of the
33 092 women in active follow-up at 108 months, we
excluded 1722 women with missing RLS information,
leaving a total of 31 370 women for this analysis.
2 Szentkirályi A, Winter AC, Schürks M, et al. BMJ Open 2012;2:e001652. doi:10.1136/bmjopen-2012-001652
Restless legs syndrome and mortalityPHYSICIANS’ HEALTH STUDY
The Physicians’ Health Study I (PHS I) was a rando-
mised, double-blind, placebo-controlled trial to test the
beneﬁts and risks of low-dose aspirin (325 mg) and
β-carotene (50 mg) in the primary prevention of CVD
and cancer among 22 071 apparently healthy male physi-
cians aged 40–84 years at baseline in 1982.
22 Baseline
information was self-reported and collected by means of
a mailed questionnaire that asked about many cardiovas-
cular risk factors and life style variables. Every 6 months
in the ﬁrst year and yearly thereafter, follow-up question-
naires were sent to the participants. Since the trials’ ter-
mination in 1995, the men are continued to be followed
either on an observational basis or as part of the PHS II.
Using methods successfully developed in the PHS I,
the PHS II was launched in 1997.
23 The PHS II is an
ongoing randomised, double-blind, placebo-controlled
trial to test the effects of vitamin C (500 mg), vitamin E
(400 IU), β-carotene (50 mg), and a daily multivitamin
(Centrum Silver) in the prevention of total and prostate
cancer, CVD and age-related eye disease among 14 641
US male physicians aged 55 years and older, including a
total of 7 641 PHS I participants who were willing and
eligible to enter the PHS II. Baseline information was
self-reported and follow-up information was collected
annually by mailed questionnaires. For the purpose of
this analysis, we pooled data from the PHS I and PHS II,
yielding a total of 29 071 participants. The return date
of the questionnaire containing the RLS questions
(216-month questionnaire for PHS I participants and
12-month questionnaire for PHS II participants) was
deﬁned as new baseline for this analysis. At this time
point, 24 505 men were still in active follow-up. We
excluded 1579 men with missing information for all
three RLS questions, leaving a total of 22 926 men at
our deﬁned baseline for our analysis.
RLS ASSESSMENT
RLS is diagnosed according to the presence of speciﬁc
symptoms. Participants in each study were asked to
answer the following questions which were based on the
minimal criteria published by the International Restless
Legs Syndrome Study Group:
12 ‘Do you have unpleasant
leg sensations (like crawling, paraesthesias, or pain) com-
bined with a motor restlessness and an urge to move?’,
‘Do these symptoms occur only at rest and does moving
improve them?’, ‘Are these symptoms worse in the
evening or at night compared with the morning?’ The
three answer categories included ‘Yes’, ‘No’ or ‘Don’t
know’. Participants were only classiﬁed as RLS-positive if
they answered all symptom questions with ‘Yes’.
In DHS and SHIP RLS assessment was conducted in
face-to-face interviews by trained and certiﬁed inter-
viewers, while in WHS and PHS RLS information was
retrieved by mailed standardised questionnaires. The
same questions that were used to identify RLS symptoms
in each study had been previously validated
24 and had
already been used in prior reports.
2571 82 5Comparing
the questionnaire-based classiﬁcation of RLS with a phy-
sician’s diagnosis as a gold standard showed good agree-
ment (unweighted κ=0.67, p<0.001) in the German
MEMO (Memory and Morbidity in Augsburg Elderly)
study.
24 In the DHS, there was a further question related
to the number of years elapsed since the onset of RLS
symptoms. The frequency of RLS symptoms was also
assessed in the DHS with the following possible answer
categories: ‘daily’, ‘3–6 times a week’, ‘1–2 times a week’,
‘1–3 times a month’ and ‘less than once a month’. The
ﬁrst two categories and the remaining three categories
were subsequently collapsed for the analysis.
ASCERTAINMENT OF MORTALITY
Death from all causes was deﬁned as our main outcome
for the analyses. In both German cohorts, the vital status
of participants, that is, alive or deceased and the date of
death, if applicable, was retrieved from the municipal
registries at the follow-up. In both US cohorts, deaths of
participants were identiﬁed by reports from family
members or next of kin, or postal authorities, and
searches of the National Death Index. Information on
date and cause of death were conﬁrmed through review
of death certiﬁcates and medical records by an end-
points committee of physicians.
SOCIO-DEMOGRAPHIC DATA, LIFESTYLE FACTORS
AND COMORBIDITIES
Age, gender and lifestyle factors, that is, health-related
behaviours, were assessed during the interview in the
German studies and with the mailed questionnaire in
the WHS and PHS. In the DHS and SHIP, comorbidities
including diabetes mellitus, hypertension, cancer, myo-
cardial infarction and stroke were assessed as self-reports
with speciﬁc questions asking for a physician-made diag-
nosis of the respective condition. In the WHS and PHS,
these comorbidities were also assessed by questionnaires,
and the presence of myocardial infarction, stroke and
cancer was conﬁrmed by medical record review. Body
mass index (BMI) was calculated using measured height
and weight information in the German studies and self-
reported height and weight information in the US
cohorts. There was one question referring to the pres-
ence of leg cramps in SHIP.
STATISTICAL ANALYSIS
Data of the four cohort studies were analysed separately
using the following identical analysis approach. For each
cohort, we calculated mean values for continuous and
frequencies for categorical variables of baseline charac-
teristics. Person-time was calculated from the return date
of the questionnaire containing the RLS questions or
date of interview, respectively, to the date of death, last
documented contact or end of study, whatever occurred
ﬁrst. Cox proportional hazards models were used to
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Age-adjusted and multivariable-adjusted HRs and their
95% CIs were calculated. The multivariable models were
adjusted for the following potential confounding factors:
age, gender (DHS and SHIP), BMI, smoking, exercise,
history of diabetes, history of hypertension, myocardial
infarction, stroke and cancer. To provide comparability of
results across studies, we additionally performed stratiﬁed
analyses according to gender in the DHS and SHIP.
The proportional hazards assumption was tested by
including an interaction term for RLS status and loga-
rithm of follow-up time for mortality in age-adjusted
models. We found no statistically signiﬁcant violation.
In all multivariable models participants with missing
covariate information were excluded. The models were
reanalysed incorporating a missing value indicator in the
outcome models for covariates if the number of partici-
pants with missing information was greater or equal to
100. We assigned participants with missing values to the
covariate reference category if the number of missing
information was less than 100. These analyses provided
nearly identical results (data not shown).
We performed several sensitivity analyses. First, we
excluded participants who reported leg cramps in SHIP
since the presence of leg cramps is a potential RLS
mimic. Second, we evaluated whether RLS frequency is
associated with RLS mortality in the DHS. Third, we
assessed whether the number of years elapsed since the
onset of RLS has an effect on RLS mortality in the DHS.
All analyses were performed with Stata V.11.0
(StataCorp, Texas, USA) in the DHS and SHIP. For all
WHS and PHS analyses, we used SAS V.9.1.3 (SAS
Institute Inc, Cary, North Carolina, USA). All p values
were two-tailed and p<0.05 was considered statistically
signiﬁcant.
RESULTS
Baseline characteristics
Table 1 summarises the baseline characteristics of parti-
cipants in the four different cohorts. The mean age in
the cohorts ranged from 50.3 years in SHIP to 67.8 years
in the PHS. The prevalence of RLS at baseline varied
between 7.4% in DHS and 11.9% in WHS. Baseline RLS
prevalence was signiﬁcantly higher among women than
in men in both German cohorts (9.3% vs 5.2%, p=0.005
in DHS and 12.8% vs 7.3%, p<0.001 in SHIP).
RLS and mortality
The median follow-up time, the number of deaths and
the death rate for each study are presented in table 2.
The highest death rate was observed in the PHS (12.3/
1000 person-years) and the lowest death rate was mea-
sured in the WHS (2.8/1000 person-years).
Tables 3 and 4 summarise the age-adjusted and
multivariable-adjusted HRs (95% CI) for the association
between RLS and mortality. RLS was not signiﬁcantly
associated with mortality in any of the four studies.
Multivariable-adjusted HRs (95% CI) ranged from 0.21
(0.03 to 1.53) in the DHS to 1.07 (0.93 to 1.23) in the
PHS. After gender stratiﬁcation the adjusted HRs were
similar among women and men in SHIP. Furthermore,
when the interaction term between RLS and gender was
added to the fully adjusted model, it was not signiﬁcant
(p=0.71). In the DHS the estimation of the HR among
women was not possible, because no women with RLS
died during the follow-up. Excluding participants who
reported leg cramps (n=370) did not substantially alter
the results in SHIP (multivariable-adjusted HR (95% CI)
0.85 (0.61 to 1.19)). When the frequency of RLS symp-
toms was entered into the model in the DHS, the HR
associated with the RLS frequency of no more than
twice a week versus no RLS symptoms was 0.39 (95% CI
0.09 to 1.63); the HR for RLS frequency of at least three
times a week versus no RLS was 1.28 (95% CI 0.45 to
3.63). Finally, when the number of years elapsed since
the onset of RLS symptoms was added to the
multivariable-adjusted model, it was not associated with
increased mortality hazard in DHS: HR=1.00 (95% CI
0.90 to 1.12).
Table 1 Baseline characteristics of participants
Dortmund Health
Study
Study of Health
in Pomerania
Physicians’ Health
Study
Women’s Health
Study
Number of participants 1299 4291 22 926 31 370
Age (years) (mean±SD) 52.2±13.8 50.3±16.4 67.8±9.0 63.6±6.9
Women, n (%) 688 (53.0) 2185 (50.9) 0 (0) 31 370 (100)
RLS, n (%) 96 (7.4) 433 (10.1) 1 717 (7.5) 3745 (11.9)
BMI (kg/m
2) (mean±SD) 27.5±5.0 27.3±4.8 25.9±3.7 27.1±5.5
Diabetes, diagnosed, n (%) 98 (7.5) 342 (8.0) 1983 (8.7) 2 342 (7.5)
Hypertension, diagnosed, n (%) 461 (35.7) 1729 (40.8) 12 079 (52.7) 15 223 (48.5)
Cancer, diagnosed, n (%) 59 (4.6) 53 (1.2) 2306 (10.1) 1818 (5.8)
Myocardial infarction,
diagnosed, n (%)
49 (3.8) 146 (3.4) 797 (3.5) 248 (0.8)
Stroke, diagnosed, n (%) 29 (2.2) 98 (2.3) 490 (2.1) 251 (0.8)
BMI, body mass index; RLS, restless legs syndrome.
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In four independently conducted large prospective
cohort studies from Germany and the USA, RLS was not
associated with all-cause mortality. The risk of death did
not differ according to gender. In contrast to the few
previous studies,
16 17 we applied standardised questions
of the minimal diagnostic criteria to assess RLS and we
also accounted for numerous explanatory variables.
COMPARISONS WITH OTHER STUDIES
Some clinic-based studies found a relationship between
RLS and mortality among subjects with end-stage renal
disease, either in dialysed
13 14 or transplanted patients.
15
There was no clear explanation for the ﬁndings, although
the presence of RLS could be related to indicators of
poorer health status, like higher level of uraemia, disease
duration and comorbidity. However, those studies were
conducted in a very speciﬁc patient group with very high
morbidity and mortality, and thus the results can be hardly
generalised to relatively healthier populations like ours.
In prior reports of community-dwelling elderly sub-
jects, RLS symptoms indicated higher mortality only
among women.
16 Mallon et al found that RLS combined
with daytime sleepiness was associated with increased
mortality risk among women in a middle-aged popula-
tion, although RLS without sleepiness was not signiﬁ-
cantly related to mortality.
17 There was no clear
explanation for these ﬁndings, though it has been
speculated that disturbed sleep, which frequently accom-
panies severe RLS, might contribute to the decreased
lifespan of subjects with RLS. We had no data about
daytime sleepiness or other sleep variables available to
determine whether these factors modify the relationship
between RLS and mortality.
Differences in sampling and population characteristics
might have contributed to the discrepant ﬁndings
between the previous and the present studies. More
importantly, at the time of the baseline assessment of
the two earlier studies, standard criteria for RLS did not
exist. The urge to move the legs and relief of symptoms
due to leg movement, two core symptoms of RLS, were
not assessed. It should be also noted that the follow-up
time of the study of Mallon et al
17 was 20 years, much
longer than any of our studies.
In contrast to these previous results, recently pub-
lished analyses from the WHS and PHS cohorts do not
suggest that RLS is associated with incident cardiovascu-
lar disease events including CVD mortality, either in
women or men.
25 However, another recent report
Table 3 Age-adjusted, gender-adjusted and multivariable-adjusted HRs and 95% CIs for mortality according to RLS status
in the German cohorts
Dortmund Health Study Study of Health in Pomerania
HR (95% CI)
Age-adjusted and gender-adjusted models n=1299 n=4291
Total 0.21 (0.03 to 1.49) 1.04 (0.81 to 1.34)
Male 0.42 (0.06 to 3.09) 1.00 (0.71 to 1.39)
Female n.a. 1.13 (0.77 to 1.67)
Multivariable-adjusted* models n=1283 n=4264
Total 0.21 (0.03 to 1.53) 0.99 (0.76 to 1.29)
Male 0.52 (0.07 to 3.95) 0.98 (0.68 to1.39)
Female NA 1.00 (0.66 to 1.50)
*Multivariable models were adjusted for age, gender, body mass index, smoking, physical activity and histories of diabetes, hypertension,
myocardial infarction, stroke and cancer.
NA, not available; RLS, restless legs syndrome.
Table 2 Follow-up status of participants
Dortmund Health
Study
Study of Health
in Pomerania
Physicians’ Health
Study
Women’s Health
study
Number of participants 1299 4291 22 926 31 370
Median follow-up time (IQR) 6.9 (0.3) 11.1 (1.5) 8.7 (0.6) 6.5 (0.8)
Number of deaths (%)
Total 55 (4.2) 540 (12.6) 2 287 (10.0) 542 (1.7)
Among participants with RLS 1 (1.0) 70 (16.2) 215 (12.5) 63 (1.7)
Among participants without RLS 54 (4.5) 470 (12.2) 2072 (9.8) 479 (1.7)
Mortality rate per 1000 person
per year (95% CI)
6.2 (4.7 to 8.1) 11.8 (10.9 to 12.9) 12.3 (11.8 to 12.8) 2.8 (2.5-3.0)
RLS, restless legs syndrome.
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an independent predictor of coronary heart disease
among women.
26
Subjective and objective sleep disturbances are very
common among subjects with RLS.
27 28 Both short sleep
duration and frequent insomnia symptoms predict mor-
tality according to population-based and community-
based studies.
29 30 Thus we cannot rule out that patients
experiencing RLS combined with chronic severe sleep
deprivation and/or insomnia may have a higher mortal-
ity risk over time. Future prospective studies with assess-
ment of RLS severity as well as various sleep-related
factors should further investigate this hypothesis.
STRENGTHS AND LIMITATIONS
One of the strengths of the present work is the analysis
of four independently conducted cohort studies. The
lack of association observed across the four different
studies indicates the robustness of our ﬁnding.
Furthermore, RLS cases were classiﬁed according to the
minimal criteria for RLS. There were differences in the
sampling procedures, sample characteristics and base-
line data collection across the studies. However, the fact
that the results of a null association were the same
despite these differences underlines the robustness of
the lack of association between RLS and mortality.
Finally, we were able to take several important potential
confounders into account, including behavioural risk
factors and comorbid conditions.
Several limitations have to be considered when inter-
preting our results. An important limitation is that, as in
all large epidemiological studies, case classiﬁcation was
based on a set of self-administered diagnostic questions
instead of a complete clinical interview and examin-
ation. However, the set of RLS questions used in our
cohorts has been successfully used and validated in pre-
vious studies and the observed prevalences in our
cohorts are similar to those reported in other
population-based studies.
31 We also note that conducting
clinical interviews in large studies like these would have
been extremely difﬁcult. Still, the use of screening ques-
tions could have led to misclassiﬁcation, and RLS
mimics could have been falsely identiﬁed as RLS cases.
We adjusted for the presence of diabetes, therefore dia-
betic neuropathy, a common potential RLS mimic, was
not likely to inﬂuence the ﬁndings. In SHIP, excluding
participants with leg cramps, another frequent RLS
mimic, did not substantially alter the results.
Nevertheless, there might be other potential mimics of
RLS symptoms that could have an effect on the associ-
ation between RLS and mortality. Due to the low
number of outcome events in the DHS, the estimates for
the association of RLS with mortality were less precise
than in the other three cohorts. It is possible that a
longer follow-up time might have revealed an association
between RLS and mortality. Information on frequency
and duration of RLS symptoms was available in only one
of the cohorts. Despite adjustments for a large number
of potential confounders, residual and unmeasureable
confounding remains possible as our study is observa-
tional. However, we are not aware of any confounding
factor that, if included in our ﬁnal models, would result
in increased risk of all-cause mortality among patients
with RLS. Participants in all four cohorts were predom-
inately white, which may limit the generalisability to
other populations.
CLINICAL IMPLICATIONS
Results of these four independent large cohort studies
do not suggest that RLS is a risk factor for mortality.
However, previous studies indicate that RLS is associated
with a variety of comorbidities, such as diabetes, higher
body mass index and cardiovascular diseases, which are
established risk factors for mortality. Patients with RLS
should be screened for RLS associated comorbidities
and treated if necessary.
UNANSWERED QUESTIONS AND FUTURE RESEARCH
RLS is a highly prevalent disease among the elderly, but
the mechanisms causing the disease and its relationship
with a diverse set of comorbidities remain poorly under-
stood. In addition, sleep deprivation and insomnia
accompanying RLS may also inﬂuence mortality and
comorbidity. Further studies are warranted to establish
risk factors for incident RLS to be able to develop sufﬁ-
cient prevention strategies and to understand the
complex relationship between RLS and its comorbid con-
ditions. In the DHS, the frequency and duration of RLS
symptoms were not related to mortality, even though the
effect size increased with symptom frequency. Since this
was the smallest study with the youngest population, the
potential role of RLS severity needs further clariﬁcation.
Finally, RLS as a potential mortality hazard should be
further investigated with longer follow-up time and in
Table 4 Age-adjusted and multivariable-adjusted HRs
and 95% CIs for mortality according to RLS status in the
US cohorts
Women’s
Health
Study
Physicians’
Health Study
HR (95% CI)
Age-adjusted models n=31 370 n=22 926
0.98
(0.75 to 1.27)
1.10
(0.96 to 1.27)
Multivariable-adjusted*
models
n=30 475 n=22 816
0.93
(0.71 to 1.21)
1.07
(0.93 to 1.23)
*Multivariable models were adjusted for age, body mass index,
smoking, physical activity and histories of diabetes, hypertension,
myocardial infarction, stroke and cancer.
RLS, restless legs syndrome.
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Restless legs syndrome and mortalityhigh-risk populations, for example among elderly
subjects.
In summary, results of four independent large, pro-
spective cohort studies indicate that RLS is not asso-
ciated with increased risk of all-cause mortality. Given
the high prevalence of RLS in western populations, this
is a positive result for all living with RLS.
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